Abstract
The absolute rate of recurrence of venous thromboembolism (VTE) is approximately 5% per year. There is a lower rate of recurrence in provoked VTE, and higher in idiopathic one. So far, there is no consensus whether hereditary thrombophilia should be considered as a persistent risk factor, and whether it requires long-term anticoagulant therapy. The aim of our study was to estimate the risk of recurrent VTE in patients carrying FV Leiden mutation in Serbian population.
In retrospective study (1994–2006), we have evaluated the risk of recurrent VTE in 56 patients who are carriers of FV Leiden mutation, in comparison to group consisting of 56 patients non-carriers of FV Leiden mutation. Patients with FII G20210A and MTHFR C677T mutations, antiphospholipid antibodies, antithrombin III, protein C or protein S deficiency, malignancies and diabetes were excluded from the study.
Recurrent VTE occurred in 44.6% of the patients, carriers of the FV Leiden mutations, vs. 26.7% in non-carriers group (P < 0.05). The incidence rate was 3.7 and 2.2% per year, respectively. The estimated relative risk of recurrence for FV Leiden carriers was 1.67 (95% CI 0.99–2.81, P = 0.049). The 60% of patients with mutation and only 13% without mutation develop rethrombosis during first year after discontinuance of therapy (P < 0.01).
In our study patients with symptomatic VTE who are carriers of the FV Leiden gene mutations have a higher risk of recurrent VTE than non-carriers. Our data suggest the importance of the FV Leiden mutation detection and the estimation of the clinical condition for successful secondary prophylaxis of VTE.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dahlback B (1994) Physiological anticoagulant. Resistance to activated protein C and venous thromboembolism. J Clin Invest 94:923–927
Bertina RM (1999) Molecular risk factors for thrombosis. Thromb Haemost 82(2):601–609
Mikovic D, Rakicevic LJ, Kovac M, Radojkovic D (2000) Prevalence of factor V Leiden mutation in Yugoslav thrombophilic patients and its relationship to the laboratory diagnosis of APC resistance. Thromb Haemost 84:723–724
Djordjevic V, Rakicevic LJ, Mikovic D et al (2004) Prevalence of factor V Leiden, factor V Cambridge, factor II G20210A and methylenetetrahydrofolate reductase C677T mutations in healthy and thrombophilic Serbian populations.Acta Haematol 112:227–229
Palareti G, Legnani C, Cosmi B et al (2003) Predictive value of D-dimer test for recurrent venous thromboembolism after withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 108:313
Eichinger S, Pabinger I, Stumpfelen A et al (1997) The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 77(4):624–628
Rintelen C, Pabinger I, Knobl P, Lechner K, Manhalter C (1996) Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost 76(5):815–816
Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H and the DURAC Trial Study Group. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. Thromb Haemost 81:684–689
Ridker PM, Miletic JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH (1995) Factor V leiden and risk of recurrent idiopathic venous thromboembolism. Circulation 92:2800–2802
Simoni P, Prandoni P, Lensing A et al (1997) The risk of recurrent venous thromboembolism in patients with an Arg 506–Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 336:399–403
Marchiori A, Mosena L, Prins MH, Prandoni P (2006) The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systemic review of prospective studies. Pathophysiol Haemost Thromb 35(1–2):1016
Santamaria MG, Agnelli G, Taliani MR et al (2005) Thrombophilic Abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment. Thromb Res 116(4):301–306
Mannucci PM, Tripodi A, Bottaso B et al (1992) Markers of procoagulant imbalance in patients with inherited thrombophilic syndromes. Thromb Haemost 67(2):200–202
Martinelli I, Bottaso B, Duca F, Faioni E, Mannucci PM (1996) Heightened Thrombin generation in individuals with resistance to activated protein C. Thromb Haemost 75(5):703–705
Kovac M, Mikovic D, Rakic LJ et al (2000) Haemorrhagic syndrome in the course of oral anticoagulant therapy. J Hematol Soc Serbia Montenegro 28(1,2/3):25–29
Schulman S (1997) Optimal duration of oral anticoagulant therapy in venous thromboembolism. Thromb Haemost 78(1):693–698
Palareti G, Legnani C, Cosmi B, Guazzaloca G, Cini M, Mattarozzi S (2005) Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence. J Thromb Haemost 3:955–961
Kearon C (2004) Long-term management of patients after venous thromboembolism. Circulation 110:1–10
Christiansen SC, Cannegieter SC, Koster T, Vanderbroucke JP, Rosendaal FR (2005) Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 293(19):2352–2361
Acknowledgements
This work was supported by grant 143051 from Ministry for Science and Environmental Protection of Serbia.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kovac, M., Mikovic, D., Antonijevic, N. et al. FV Leiden mutation and risk of recurrent venous thromboembolism in Serbian population. J Thromb Thrombolysis 25, 284–287 (2008). https://doi.org/10.1007/s11239-007-0059-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-007-0059-z